This bill addresses the regulation of direct acting antiviral medications, specifically focusing on hepatitis C treatments within the Iowa medical assistance program. It stipulates that the Iowa Department of Health and Human Services will not require prior authorization for any direct acting antiviral medications that are included on the preferred drug list. This change aims to streamline access to these essential medications for patients in need of hepatitis C treatment.

Additionally, the bill mandates that the Iowa Medical Assistance Drug Utilization Review Commission conduct a review of the prescription drug vosevi by July 1, 2026. The purpose of this review is to determine whether vosevi should be included on the preferred drug formulary as a direct acting antiviral for hepatitis C treatment, in accordance with federal regulations. This provision seeks to ensure that patients have access to the most effective treatment options available.